Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics Study

Assessment of Insulin Sensitivity in Type 2 Diabetics Treated With Metformin, Fenofibrate and Their Combination.

Double-blind, randomized placebo-controlled study in type 2 diabetes and dyslipidemic patients.Patients will be randomized to one of four treatment arms for 16 weeks: placebo, fenofibrate, metformin, or metformin and fenofibrate combination.

Inclusion Criteria:

• Patients with type 2 diabetes mellitus and dyslipidemia.

Exclusion Criteria:

• Type 1 diabetes.